Personalized Medicine Approaches Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Personalized Medicine Approaches. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Personalized Medicine Approaches Indian Medical PG Question 1: Pharmacodynamics deals with:-
- A. Latency of onset
- B. Mechanism of action of a drug (Correct Answer)
- C. Transport of drug across the biological membranes
- D. Mode of excretion of a drug
Personalized Medicine Approaches Explanation: Detailed study of the **Mechanism of action of a drug** [1][2]
- **Pharmacodynamics** describes what the **drug does to the body**, including its **molecular targets** and biochemical effects [3].
- This involves the study of the drug's mechanisms to produce its therapeutic or toxic effects [2].
*Latency of onset*
- **Latency of onset** refers to the time it takes for a drug to start producing its effects, which is a pharmacokinetic rather than a pharmacodynamic parameter.
- It deals with the drug's absorption and distribution rather than its interaction with the body once it reaches its site of action.
*Transport of drug across the biological membranes*
- The **transport of drugs across biological membranes** is a key aspect of **pharmacokinetics**, specifically absorption and distribution [1].
- This process determines how much drug reaches its target site, not how it interacts with the target.
*Mode of excretion of a drug*
- The **mode of excretion** of a drug (e.g., renal, hepatic) falls under **pharmacokinetics**, addressing how the body gets rid of the drug.
- This process influences the drug's duration of action and elimination half-life, not its mechanism of action.
Personalized Medicine Approaches Indian Medical PG Question 2: Match the following drugs with the targets of their actions:
Drugs:
A. Trastuzumab
B. Infliximab
C. Sirolimus
D. Imatinib
Targets:
1. BCR-ABL tyrosine kinase
2. mTOR
3. TNF alpha
4. HER2/neu
- A. A-2, B-3, C-1, D-4
- B. A-3, B-4, C-2, D-1
- C. A-4, B-3, C-1, D-2
- D. A-4, B-3, C-2, D-1 (Correct Answer)
Personalized Medicine Approaches Explanation: ***Correct Answer: A-4, B-3, C-2, D-1***
- **Trastuzumab** (Herceptin) is a **monoclonal antibody** that targets the **HER2/neu receptor (4)** [1], [2], commonly overexpressed in certain breast cancers and gastric cancers.
- **Infliximab** is another **monoclonal antibody** that specifically targets and neutralizes **TNF-alpha (3)**, an inflammatory cytokine, making it useful in treating autoimmune diseases like rheumatoid arthritis and Crohn's disease.
- **Sirolimus** is an **immunosuppressant** drug that inhibits the mammalian target of rapamycin (**mTOR (2)**), a protein kinase involved in cell growth and proliferation, used in transplant medicine and as an anticancer agent.
- **Imatinib** is a **tyrosine kinase inhibitor** that primarily targets the **BCR-ABL fusion protein (1)** [1], [2], which is characteristic of chronic myeloid leukemia.
*Incorrect: A-2, B-3, C-1, D-4*
- This option incorrectly matches Trastuzumab with mTOR and Sirolimus with BCR-ABL, which are not their primary targets.
- Trastuzumab targets HER2/neu [1], [2], and Sirolimus targets mTOR.
*Incorrect: A-3, B-4, C-2, D-1*
- This option incorrectly matches Trastuzumab with TNF-alpha and Infliximab with HER2/neu.
- Infliximab targets TNF-alpha, and Trastuzumab targets HER2/neu [1], [2].
*Incorrect: A-4, B-3, C-1, D-2*
- This option incorrectly matches Sirolimus with BCR-ABL and Imatinib with mTOR.
- Sirolimus inhibits mTOR, and Imatinib inhibits BCR-ABL [1], [2].
Personalized Medicine Approaches Indian Medical PG Question 3: What is the mechanism of action of Warfarin?
- A. Inhibition of Vitamin K epoxide reductase (Correct Answer)
- B. Inhibition of gamma glutamyl carboxylase
- C. Activation of Vitamin K epoxide reductase
- D. Activation of gamma glutamyl carboxylase
Personalized Medicine Approaches Explanation: ***Inhibition of Vitamin K epoxide reductase***
- Warfarin blocks **Vitamin K epoxide reductase (VKORC1)** [1, 2, 3], an enzyme essential for recycling oxidized vitamin K into its active reduced form [1, 3].
- This reduction prevents the activation of **vitamin K-dependent clotting factors** (II, VII, IX, X), leading to anticoagulation [1, 3].
*Inhibition of gamma glutamyl carboxylase*
- **Gamma-glutamyl carboxylase** uses reduced vitamin K as a cofactor to carboxylate specific glutamic acid residues on clotting factors [1, 3].
- While essential for clotting factor activation, this enzyme itself is **not directly inhibited by warfarin** [1, 3].
*Activation of Vitamin K epoxide reductase*
- Activating **VKORC1** would increase the production of reduced vitamin K, thereby **promoting coagulation** rather than inhibiting it [1, 2].
- This is the opposite of warfarin's intended therapeutic effect.
*Activation of gamma glutamyl carboxylase*
- Activating **gamma-glutamyl carboxylase** would enhance the carboxylation and activation of **clotting factors**, leading to procoagulant effects [1, 3].
- This mechanism contradicts warfarin's role as an **anticoagulant**.
Personalized Medicine Approaches Indian Medical PG Question 4: Which of the following is not considered a pharmacogenetic condition?
- A. Adenosine deaminase deficiency (Correct Answer)
- B. Coumarin insensitivity
- C. G6PD deficiency
- D. Malignant hyperthermia
Personalized Medicine Approaches Explanation: ***Adenosine deaminase deficiency***
- **Adenosine deaminase deficiency** (ADA deficiency) is an **autosomal recessive** metabolic disorder causing severe immunodeficiency, primarily affecting gene function rather than drug response.
- While it can be treated with enzyme replacement therapies or gene therapy, it is not primarily characterized by an altered response to standard therapeutic drugs.
*Coumarin insensitivity*
- **Coumarin insensitivity** refers to an individual's reduced response to **warfarin (a coumarin derivative)**, requiring higher doses to achieve effective anticoagulation.
- This is a well-documented **pharmacogenetic condition**, often linked to variations in genes like *CYP2C9* and *VKORC1*.
*G6PD deficiency*
- **Glucose-6-phosphate dehydrogenase (G6PD) deficiency** is an X-linked genetic disorder that can lead to **hemolytic anemia** upon exposure to certain drugs (e.g., antimalarials, sulfonamides, aspirin) and fava beans [1].
- It is a classic example of a **pharmacogenetic condition** where genetic variations dictate drug-induced adverse reactions [1].
*Malignant hyperthermia*
- **Malignant hyperthermia** is a life-threatening, inherited disorder triggered by certain **inhalation anesthetics** (e.g., halothane, isoflurane) and the **depolarizing muscle relaxant succinylcholine**.
- This condition is caused by mutations in genes involved in calcium regulation in muscle cells (e.g., *RYR1*) and is a critical **pharmacogenetic response**.
Personalized Medicine Approaches Indian Medical PG Question 5: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
- A. First pass kinetics
- B. First order kinetics
- C. Zero order kinetics (Correct Answer)
- D. Second order kinetics
Personalized Medicine Approaches Explanation: ***Zero order kinetics***
- This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time.
- Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses.
*First pass kinetics*
- This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration.
- While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses.
*First order kinetics*
- In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration.
- Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated.
*Second order kinetics*
- This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants.
- It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.
Personalized Medicine Approaches Indian Medical PG Question 6: Which of the following clotting factors in a patient on Warfarin therapy would show the earliest decrease in functional activity?
- A. Factor VII (Correct Answer)
- B. Factor IX
- C. Factor X
- D. Prothrombin (Factor 2)
Personalized Medicine Approaches Explanation: ***Factor VII***
- Factor VII has the **shortest half-life** (approximately 6 hours) among the vitamin K-dependent clotting factors, meaning its functional activity decreases **most rapidly** after starting warfarin therapy.
- Warfarin inhibits vitamin K epoxide reductase, preventing gamma-carboxylation of **all vitamin K-dependent factors** (II, VII, IX, X). However, Factor VII's short half-life means pre-existing functional Factor VII is depleted first.
- This is why **PT/INR** (which measures the extrinsic pathway dependent on Factor VII) rises before aPTT in warfarin therapy.
- Reduced gamma-carboxylation impairs Factor VII's ability to bind calcium and phospholipids, essential for its activation in the extrinsic coagulation pathway.
*Factor IX*
- Factor IX is a **vitamin K-dependent factor** affected by warfarin, but its longer half-life (approximately 24 hours) means functional activity decreases more slowly than Factor VII.
- It plays a key role in the **intrinsic coagulation pathway**.
*Factor X*
- Factor X is a **vitamin K-dependent clotting factor** whose gamma-carboxylation is inhibited by warfarin.
- Its half-life (approximately 40 hours) is longer than Factor VII, resulting in a **slower decline in functional activity**.
*Prothrombin (Factor II)*
- Prothrombin (Factor II) is a **vitamin K-dependent factor** affected by warfarin.
- It has the **longest half-life** (60-72 hours) among vitamin K-dependent factors, meaning its functional levels decrease most slowly after initiating warfarin therapy.
Personalized Medicine Approaches Indian Medical PG Question 7: Match the following drugs in Column A with their contraindications in Column B.
| Column A | Column B |
| :-- | :-- |
| 1. Morphine | 1. QT prolongation |
| 2. Amiodarone | 2. Thromboembolism |
| 3. Vigabatrin | 3. Pregnancy |
| 4. Estrogen preparations | 4. Head injury |
- A. A-1, B-3, C-2, D-4
- B. A-4, B-1, C-3, D-2 (Correct Answer)
- C. A-3, B-2, C-4, D-1
- D. A-2, B-4, C-1, D-3
Personalized Medicine Approaches Explanation: ***A-4, B-1, C-3, D-2***
- **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms.
- **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes.
- **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development.
- **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation.
*A-1, B-3, C-2, D-4*
- This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications.
- It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy.
*A-3, B-2, C-4, D-1*
- This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications.
- It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation.
*A-2, B-4, C-1, D-3*
- This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications.
- It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.
Personalized Medicine Approaches Indian Medical PG Question 8: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
- A. Amiodarone + Atorvastatin
- B. Carbamazepine + Atorvastatin
- C. Atorvastatin + Itraconazole (Correct Answer)
- D. Phenytoin + Atorvastatin
Personalized Medicine Approaches Explanation: ***Atorvastatin + Itraconazole***
- **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism.
- Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**.
*Amiodarone + Atorvastatin*
- **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole.
- While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole.
- The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole.
*Carbamazepine + Atorvastatin*
- **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition.
- This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity.
*Phenytoin + Atorvastatin*
- **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine.
- Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.
Personalized Medicine Approaches Indian Medical PG Question 9: Treatment with Herceptin in breast cancer is indicated for
- A. Tumours with over-expressed HER2/C-erbB-2 protein (Correct Answer)
- B. PR receptor +ve tumours
- C. ER receptor +ve tumours
- D. Ki-67 stain +ve tumours
Personalized Medicine Approaches Explanation: **tumours with over-expressed C-erb B-2 protein**
- **Herceptin** (trastuzumab) is a monoclonal antibody that specifically targets the **HER2/neu receptor**, which is encoded by the *ERBB2* gene.
- Its efficacy depends on the **overexpression of C-erbB-2 protein** (also known as HER2/neu) on the surface of breast cancer cells, which indicates **HER2-positive breast cancer**.
*K : 67 stain +ve tumours*
- **Ki-67** is a proliferation marker that indicates the **growth fraction of a tumor**, and a positive stain suggests a rapidly dividing tumor.
- While Ki-67 positivity is associated with more aggressive tumors, it does **not directly indicate suitability for Herceptin** treatment.
*PR receptor +ve tumours*
- Tumors positive for the **progesterone receptor (PR)** are typically treated with **hormonal therapies**, such as tamoxifen or aromatase inhibitors.
- **PR positivity** does not indicate responsiveness to Herceptin, which targets the HER2 receptor.
*ER receptor +ve tumours*
- Tumors positive for the **estrogen receptor (ER)** are also treated with **hormonal therapies** due to their dependence on estrogen for growth.
- Similarly to PR-positive tumors, **ER positivity** does not determine eligibility for Herceptin therapy.
Personalized Medicine Approaches Indian Medical PG Question 10: Testing of HLA-B' 5701 is recommended prior to initiation of which antiretroviral agent?
- A. Atazanavir
- B. Nelfinavir
- C. Raltegravir
- D. Abacavir (Correct Answer)
Personalized Medicine Approaches Explanation: The correct answer is **Abacavir (Option D)**.
**1. Why Abacavir is Correct:**
Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) associated with a severe, potentially life-threatening **Hypersensitivity Reaction (HSR)** [1]. This reaction is strongly linked to the presence of the **HLA-B*57:01** allele. In individuals carrying this allele, abacavir binds to the HLA-B*57:01 protein, altering the shape of the antigen-binding cleft [1]. This causes the immune system to recognize self-peptides as foreign, triggering a massive T-cell response. Screening for this allele is now a standard of care; if a patient tests positive, abacavir is strictly contraindicated [1].
**2. Why Other Options are Incorrect:**
* **Atazanavir (A):** A Protease Inhibitor (PI) known for causing unconjugated hyperbilirubinemia (jaundice) by inhibiting the UGT1A1 enzyme, but it is not linked to HLA-B*57:01 [1].
* **Nelfinavir (B):** An older PI primarily associated with gastrointestinal side effects (diarrhea). No specific HLA screening is required.
* **Raltegravir (C):** An Integrase Strand Transfer Inhibitor (INSTI). While it can rarely cause Stevens-Johnson Syndrome (SJS), there is no routine pharmacogenetic screening recommended prior to its use.
**3. High-Yield Clinical Pearls for NEET-PG:**
* **Abacavir HSR Symptoms:** Fever, rash, GI distress, and respiratory symptoms. **Re-challenge** after a suspected reaction is **fatal**.
* **Other High-Yield HLA Associations:**
* **HLA-B*15:02:** Carbamazepine-induced SJS/TEN (specifically in Asian populations).
* **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR).
* **Mnemonic:** "A-B-C" — **A**bacavir **B**inds **C**left of HLA-B*57:01.
More Personalized Medicine Approaches Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
